The rise of cardiovascular medicine.

Modern cardiology was born at the turn of the nineteenth to twentieth centuries with three great discoveries: the X ray, the sphygmomanometer, and the electrocardiograph. This was followed by cardiac catheterization, which led to coronary angiography and to percutaneous coronary intervention. The coronary care units and early reperfusion reduced the early mortality owing to acute myocardial infarction, and the discovery of coronary risk factors led to the development of Preventive Cardiology. Other major advances include several cardiac imaging techniques, the birth and development of cardiac surgery, and the control of cardiac arrhythmias. The treatment of heart failure, although greatly improved, remains a challenge. Current cardiology practice is evidence-based and global in scope. Research and practice are increasingly conducted in cardiovascular centres and institutes. It is likely that in the future, a greater emphasis will be placed on prevention, which will be enhanced by genetic information.

Fifty years of work on the artificial placenta: milestones in the history of extracorporeal support of the premature newborn.

The concept of an artificial placenta has been pursued in experimental research since the early 1960s. The principle has yet to be successfully implemented in neonatal care despite the constant evolution in extracorporeal life support technology and advancements in neonatal intensive care in general. For more than three decades, the physical dimensions of the required equipment necessitated pump-driven circuits; however, recent advances in oxygenator technology have allowed exploration of the simpler and physiologically preferable concept of pumpless arteriovenous oxygenation. We expect that further miniaturization of the extracorporeal circuit will allow the implementation of the concept into clinical application as an assist device. To this end, NeonatOx (Fig. 1), a custom-made miniaturized oxygenator with a filling volume of 20 mL, designed by our own group, has been successfully implemented with a preterm lamb model of less than 2000 g body weight as an assist device. We provide an overview of milestones in the history of extracorporeal membrane oxygenation of the preterm newborn juxtaposed against current and future technological advancements. Key limitations, which need to be addressed in order to make mechanical gas exchange a clinical treatment option of prematurity-related lung failure, are also identified.

The history of interventional nephrology.

Visionary nephrologists in the early 1960s invented the dialysis machine, constructed arteriovenous shunts and fistulas, and designed vascular and peritoneal catheters to provide their patients with long-term dialysis. As the number of dialysis patients grew, the construction and care of vascular access was abandoned by nephrologists to surgeons and radiologists. There was a decline in the number of fistulas and an increase in grafts in the United States. Vascular access was not the first priority for the nonnephrologists, and this set the stage for the emergence of diagnostic and interventional nephrologists. These self-taught nephrologists trained others, resulting in a critical mass of subspecialists who founded the Society of Diagnostic and Interventional Nephrology. This review traces the origin of this exciting field from its pioneers to the society as it exists today. The future of this society depends on academic nephrology fellowship programs fostering training and research in this field.

Historical reflections on the management of acute limb ischemia.

The history of clot removal consists primarily of efforts at procedures, techniques, and instruments that had suboptimal performance. In the 1960s, the amputation and death rates following attempts at removal were as high as 50%. A wide variety of instruments were used but none were specifically designed for embolus and thrombus removal. The need was obvious but the problem was unresolved.

Aortic balloon valvuloplasty--review and case series.

Aortic balloon valvuloplasty (BAV) was initially devised in the 1980s as an alternative procedure to the surgical treatment of aortic stenosis, with the theory behind it being both minimally invasive as well as having a lower complication rate [Hara H, et al. Percutaneous balloon aortic valvuloplasty revisited: time for a renaissance? Circulation 2007 March;115(12):e334-8]. In practice however, the procedure was found to have a higher complication rate with only a modest haemodynamic improvement compared to the surgical approach. Most important of all it had an unacceptably high restenosis rate as a substitute for surgery [Otto CM, et al. 3-year outcome after balloon aortic balloon valvuloplasty: insights into prognosis of valvular aortic stenosis. Circulation 1994;89:642-50]. As a result, the procedure has fallen out of favour and has been abandoned at many health care facilities [Hara H, et al. Percutaneous balloon aortic valvuloplasty revisited: time for a renaissance? Circulation 2007 March;115(12):e334-8]. This article will review the management of patients with severe aortic stenosis that are unsuitable to undergo surgery.

The beginning of balloon conception and application in peripheral arterial disease.

In 1969, German-born Andreas Grntzig joined the Angiology Division at the Zurich University Hospital. He participated in the evaluation of continuous Doppler ultrasound in peripheral arterial and venous disease and discovered that the relaxation phase of the Achilles tendon reflex is prolonged during calf pain due to intermittent claudication. Soon he became interested in Dotter's technique of peripheral transluminal angioplasty (PTA) with coaxial catheters, learned the procedure from Eberhard Zeitler and developed a new balloon catheter consisting of polyvinyl chloride. He wanted to improve the results of PTA in intermittent claudication, rest pain and incipient gangrene and to minimize their complications. In February 1974 he successfully performed the first treatment in a patient with femoral artery stenosis. The catheter used had been built by him, Maria Schlumpf and their team on his kitchen table. One year later, he introduced a double-lumen version that was much easier to manipulate. The 242 patients with iliac or femoro-popliteal artery obstructions treated by Andreas Gr untzig himself were prospectively followed by Maria Schlumpf at regular intervals. The patency rate at 15 years was 82% in iliac PTA. Because of common recurrent occlusions, the corresponding number in femoral disease reached only 46%. The favorable early and late results of PTA with prototypes and early commercial products were a prerequisite for the development and first clinical application of Gr untzig's coronary balloon catheter.

Designs of devices: the vacuum aspirator and American abortion technology.

In 1965, 71% of legal abortions in the United States were performed using the surgical procedure of dilation and curettage. By 1972, a mere seven years later, approximately the same percentage (72.6%) of legal abortions in the United States were performed using a completely new abortion technology: the electrical vacuum aspirator. This article examines why, in less than a decade, electric vacuum suction became American physicians' abortion technology of choice. It focuses on factors such as political and professional feasibility (the technology was able to complement the decriminalization of abortion in the US, and the interests, abilities, commitments, and personal beliefs of physicians); clinical compatibility (it met physician/patient criteria such as safety, simplicity and effectiveness); and economic viability (it was able to adapt to market factors such as production, cost, supply/demand, availability, and distribution).